Seraly, Mark
Madow, Brian
Farkas, Michael H.
Funding for this research was provided by:
National Eye Institute (R01 EY028553)
U.S. Department of Veterans Affairs (I01 BX004695)
BrightFocus Foundation (M2019108)
Carl Marshall and Mildred Almen Reeves Foundation
Article History
Accepted: 10 March 2022
First Online: 7 April 2022
Declarations
:
: MHF is a co-inventor and patent holder (US 20180043034 A1) of an AAV-based gene therapy for PRPF31-associated retinitis pigmentosa. MS and BM have no conflicts of interest to declare.
: The contents of this manuscript do not reflect those of the Department of Veterans Affairs or the U.S. Government.